Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Donor Enriched Activated Natural Killer cells
- Development stage
- Phase 1
- Lead developer
- University of Nebraska Medical Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Donor Enriched Activated Natural Killer (DEA-NK) cells are an investigational adoptive cellular immunotherapy developed by the University of Nebraska Medical Center for the treatment of refractory myeloid malignancies. The therapy consists of natural killer (NK) cells obtained from a haploidentical (half-matched) donor, which are then enriched and activated ex vivo using cytokines to enhance their anti-leukemic activity and longevity. These activated NK cells are administered intravenously to patients on day +7 following a haploidentical stem cell transplant (Haplo-SCT) that utilizes post-transplant cyclophosphamide (PTCY). The mechanism of action involves natural killer cell-mediated cytotoxicity, where the infused cells directly target and eliminate residual tumor cells in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN).
- Other names
- Donor Enriched Activated NK cellsαβ TCR/CD19 depleted (DEA-NK) cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)NKG2D (Natural killer group 2 member D receptor)NCR1 (Natural cytotoxicity triggering receptor 1)NCR2 (Natural cytotoxicity triggering receptor 2)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))
Beyond the preview
Go deeper on Donor Enriched Activated Natural Killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Donor Enriched Activated Natural Killer cells.